Ert Pompe denied for failing step therapy by AmeriHealth Caritas?

Confirmed enzyme assay + genetic testing. Specialist Rx (geneticist or metabolic).

EPSDT for under-21 overrides state PDL limits. Orphan Drug Act + FDA approval rebut 'experimental' label. Site-of-care: home infusion appropriate for stable patients per manufacturer REMS.

## Why AmeriHealth Caritas May Apply Step Therapy to ERT for Pompe Disease

Step therapy — a requirement to try and fail a lower-cost treatment before a more expensive one is approved — is a common managed-care tool. However, applying step therapy to enzyme replacement therapy (ERT) for Pompe disease is clinically problematic: Pompe disease is a rare, progressive lysosomal storage disorder caused by a specific enzyme deficiency, and there is no therapeutic alternative that addresses the same underlying mechanism. A step-therapy requirement in this context typically reflects an administrative rule being applied without adequate review of the underlying condition.

## Why This Denial Is Appealable

Most states and federal guidance recognize that step-therapy requirements must have a clinical exception pathway when the required prior steps are medically contraindicated, not applicable to the patient's condition, or when delaying the requested treatment would cause serious harm. For a rare disease with a narrow FDA-approved treatment class, the "step" being required often does not apply, making this a strong appeal.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial letter. Request expedited review given the progressive nature of Pompe disease — AmeriHealth Caritas must respond to expedited appeals within 72 hours.
• External review (ACA §2719): If the internal appeal is denied, an IRO will evaluate whether the step-therapy requirement is consistent with generally accepted clinical standards for this specific diagnosis. Rare disease cases often fare well at external review.
• State step-therapy exception law: Many states have enacted step-therapy exception statutes that require insurers to grant exceptions when the required drug is contraindicated, ineffective, or not appropriate for the condition. Check whether your state has such a law and cite it in your appeal.
• ERISA §503: For employer-sponsored plans, request the full claims file and the specific clinical basis for requiring the step.

The external-review window is typically four months from final internal denial.

## Documentation to Gather

• Diagnosis documentation: Genetic confirmation (GAA gene mutation analysis) and/or enzyme activity testing establishing the Pompe disease diagnosis, interpreted by a metabolic or neuromuscular specialist.
• Medical necessity letter addressing step-therapy inapplicability: A detailed letter from the treating specialist explaining why the required prior-step therapy (whatever the insurer specified) is not clinically appropriate, applicable, or available for this patient's specific diagnosis.
• Disease progression records: Clinical notes, functional assessments, and respiratory evaluations showing the current status and trajectory — establishing that delay would cause measurable harm.
• FDA label: The prescribing label for the requested ERT product, confirming it is the appropriate treatment for this diagnosis.
• Specialist-society guidance: Reference (by organization name) the applicable specialist-society guidelines that support ERT as the standard of care for Pompe disease.

## Criteria-Mapping Structure

Obtain the AmeriHealth Caritas step-therapy policy and any exception criteria. Address each element directly:

| Step-Therapy Requirement | Clinical Response | |---|---| | Required prior drug(s) | [Explain why each is not clinically applicable to this diagnosis] | | Exception: contraindication | [Prescriber statement on applicability] | | Exception: disease-specific standard of care | [Specialist letter + guideline organization citation] | | Exception: clinical urgency / harm from delay | [Functional assessment + progression documentation] |

Framing the appeal as a step-therapy exception — rather than a general appeal — is the most direct path to reversal for rare-disease enzyme deficiency conditions.